Hepatitis C virus management: potential impact of nanotechnology

Around 170-200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3-5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had b...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2017-05, Vol.14 (1), p.88-88, Article 88
Main Authors: Elberry, Mostafa H, Darwish, Noureldien H E, Mousa, Shaker A
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - therapeutic use
Bioavailability
Biomedical materials
Drug delivery system
Drug Delivery Systems - methods
Drug resistance
Drug Therapy, Combination
Gene expression
Genomes
Genotype
HCV genotypes
Hepacivirus - genetics
Hepacivirus - immunology
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatitis C, Chronic - prevention & control
Hepatitis C, Chronic - virology
Humans
Infections
Interferon
Ligands
Liver diseases
MicroRNAs - pharmacology
Nanomaterials
Nanoparticles
Nanoparticles - virology
Nanotechnology
Nanotechnology - methods
Peptides
Polyethylene glycol
Review
Ribavirin
Ribavirin - therapeutic use
RNA polymerase
Side effects
Substance abuse treatment
Vaccines
Viral Vaccines - chemistry
Viral Vaccines - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Around 170-200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3-5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had been no effective vaccine for HCV; a combination of PEG-Interferon and ribavirin for at least 48 weeks was the standard therapy, but it failed in more than 40% of the patients and has a high cost and serious side effects. The recent introduction of direct-acting antivirals (DAA) resulted in major advances toward the cure of HCV. However, relapse and reduced antiviral efficacy in fibrotic, cirrhotic HCV patients in addition to some undesired effects restrain the full potential of these combinations. There is a need for new approaches for the combinations of different DAA and their targeted delivery using novel nanotechnology approaches. In this review, the role of nanoparticles as a carrier for HCV vaccines, anti-HCV combinations, and their targeted delivery are discussed.
ISSN:1743-422X
1743-422X
DOI:10.1186/s12985-017-0753-1